TRUQAP 200 mg film-coated tablets, TRUQAP 160 mg film-coated tablets clinical trials

A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

This study is testing a new tablet medicine, Capivasertib (also called TRUQAP), for people in the UK with B-cell non-Hodgkin lymphoma that has come back or hasn't responded to previous treatments. Researchers want to see if it shrinks the cancer and if it's safe to use.